Estimating the effects of second-line therapy for type 2 diabetes mellitus: retrospective cohort study.

about

Estimating the effects of second-line therapy for type 2 diabetes mellitus: retrospective cohort study.

Item

http://www.wikidata.org/entity/Q47160310

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Estimating the effects of seco ...... s: retrospective cohort study.

@en

Estimating the effects of seco ...... s: retrospective cohort study.

@nl

type

Item

label

Estimating the effects of seco ...... s: retrospective cohort study.

@en

Estimating the effects of seco ...... s: retrospective cohort study.

@nl

prefLabel

Estimating the effects of seco ...... s: retrospective cohort study.

@en

Estimating the effects of seco ...... s: retrospective cohort study.

@nl

P1476

Estimating the effects of seco ...... us: retrospective cohort study

@en

P2093

Amos Cahan

http://www.w3.org/2001/XMLSchema#string

Assaf Gottlieb

http://www.w3.org/2001/XMLSchema#string

Yaara Goldschmidt

http://www.w3.org/2001/XMLSchema#string

P2860

HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial.

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Estimating causal effects in observational studies using Electronic Health Data: Challenges and (some) solutions

Doubly robust estimation in missing data and causal inference models.

Comorbidity measures for use with administrative data.

Defining and characterizing the progression of type 2 diabetes.

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.

Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy

Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data.

P304

e000435

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJDRC-2017-000435

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chen Yanover

P577

2017-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29299328

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5730938

http://www.w3.org/2001/XMLSchema#string